glp-1 agonists drugs Receptor Agonists: The New Wave in Diabetes Management GLP-1R Agonists for Weight Loss
Description
95%CI: 0.800.93) as well as in terms of the three individual components (cardiovascular death, myocardial infarction, and stroke)
It is unclear whether using one drug over another yields differences in cardiovascular outcomes
doi: 10.1111/obr.12839 [DOI] [PubMed] [Google Scholar] 97
Turner RC, Cull CA, Frighi V, et al
Three triple agonists are currently in clinical trials: retatrutide (Eli Lilly), HM15211 (Hanmi Pharmaceutical), and SAR441255 (Sanofi)
This hypothesized mechanism could enhance insulin secretion and suppress glucagon secretion in glucose-dependent manners (Figure 1)
